Previous Close | 27.10 |
Open | 26.40 |
Bid | 25.93 x 300 |
Ask | 26.07 x 100 |
Day's Range | 25.65 - 27.20 |
52 Week Range | 4.82 - 27.66 |
Volume | |
Avg. Volume | 1,170,046 |
Market Cap | 2.482B |
Beta (5Y Monthly) | 0.79 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.91 |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 45.88 |
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to delpacibart etedesiran (AOC 1001), the company's lead clinical development program, for the treatment of myotonic dystrophy type 1 (DM1). Delpacibart etedesiran, abbreviated as del-desiran, is an investigationa